Brind.
  1. UBS downgraded Medpace stock to 'Sell' on July 30, 2025. TD Cowen analyst also downgraded Medpace stock on the same date.

Medpace CEO provided commentary on the company's Q2 performance on July 28, 2025.

1 report, 1 independent Updated Jul 28
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Medpace CEO provided commentary on the company's Q2 performance on July 28, 2025.

Who's involved

What this event is mainly about
Medpace

Keep exploring

Part of

UBS downgraded Medpace stock to 'Sell' on July 30, 2025. TD Cowen analyst also downgraded Medpace stock on the same date. All 1 developments

The entities involved

Coverage

Newest first; wire copies grouped
  • StockStory5 Revealing Analyst Questions From Medpace’s Q2 Earnings Call Medpace’s second quarter was marked by a strong positive market reaction, driven by a combination of higher-than-expected revenue growth